Johnson & Johnson Family of Companies
NEWS
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
After nearly a year without a permanent chief executive officer Advaxis, Inc. has a new hand on the wheel. This morning the company announced Kenneth A. Berlin will take over the helm of the company as president and CEO effective immediately.
During a meeting with U.S. Food and Drug Administration Commissioner Scott Gottlieb earlier this week, government and healthcare officials in New Jersey highlighted the need to hasten the approval of new drugs and permanently eliminate the tax on medical devices.
Public health officials and scientists have had concerns about how long Ebola vaccines’ protection lasts. A new study shows that one of those vaccines confers at least two years of protection.
Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
Johnson & Johnson reported a strong first quarter with $20 billion in sales that was fueled by significant growth in its pharmaceuticals business.
JOBS
IN THE PRESS